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Cell surface Ig superfamily proteins (IgSF) have been
implicated in several aspects of neuron development
and function. Here, we describe the function of
a Caenorhabditis elegans IgSF protein, RIG-3.
Mutants lacking RIG-3 have an exaggerated paralytic
response to a cholinesterase inhibitor, aldicarb.
Although RIG-3 is expressed in motor neurons,
heightened drug responsiveness was caused by an
aldicarb-induced increase in muscle ACR-16 acetyl-
choline receptor (AChR) abundance, and a corre-
sponding potentiation of postsynaptic responses at
neuromuscular junctions. Mutants lacking RIG-3
also had defects in the anteroposterior polarity of
the ALM mechanosensory neurons. The effects of
RIG-3 on synaptic transmission and ALM polarity
were both mediated by changes in Wnt signaling,
and in particular by inhibiting CAM-1, a Ror-type
receptor tyrosine kinase that binds Wnt ligands.
These results identify RIG-3 as a regulator of Wnt
signaling, and suggest that RIG-3 has an anti-
plasticity function that prevents activity-induced
changes in postsynaptic receptor fields.
INTRODUCTION
Cell surface IgSF proteins are implicated in diverse aspects of
neuronal development, including cell and axon migration, target
recognition, axon fasciculation, axon ensheathment by glia,
synapse formation, and synapse function (Rougon and Hobert,
2003; Takeda et al., 2001; Walsh and Doherty, 1997). Many
IgSF proteins act as either homo- or heterophilic cell adhesion
molecules (CAMs), e.g., NCAM (Yamada and Nelson, 2007).
Other IgSF proteins act as receptors for secreted ligands, or as
auxiliary subunits of such receptors (Barrow and Trowsdale,
2008; Wang and Springer, 1998). IgSF proteins comprise a large
family of proteins (765 in humans, 142 in flies, 80 in worms)(Lander et al., 2001; Vogel et al., 2003) and mutations in IgSF
genes are associated with several human neurological disorders
(Fransen et al., 1997; Sun et al., 2003; Uyemura et al., 1996).
Several CAMs induce synapse formation (Biederer et al., 2002;
Kurusu et al., 2008; Linhoff et al., 2009). For example, neurexin
and neuroligin induce differentiation of post- and presynaptic
specializations, respectively (Nam and Chen, 2005; Scheiffele
et al., 2000). Some CAMs confer specificity for specific types
of synapses. Neuroligin-2 induces formation of GABA synapses,
whereas neuroligin-1 promotes formation of glutamatergic
synapses (Chih et al., 2005; Graf et al., 2004). Synaptic CAMs
also play an important role in regulating synaptic transmission.
Neurexin-neuroligin complexes recruit postsynaptic glutamate
receptors, while also altering synaptic vesicle recycling presyn-
aptically (Chubykin et al., 2007; Futai et al., 2007; Varoqueaux
et al., 2006). N-cadherin is required for homeostatic plasticity
(Goda, 2002; Okuda et al., 2007) and integrins promote LTP
(Chan et al., 2003).
Many aspects of neuron and synapse development are
regulated by both positive and negative factors. Axon and cell
migrations are shaped by gradients of secreted attractants and
repellents (Tessier-Lavigne, 1994). Similarly, synapse formation
is governed by both positive (e.g., neurexin-neuroligin) and
negative factors (e.g., Wnt) (Klassen and Shen, 2007; Poon
et al., 2008; Scheiffele, 2003). Here we show that RIG-3, a cell
surface IgSF molecule, acts as an antiplasticity molecule,
preventing a form of synaptic potentiation, and that it does so
by altering Wnt signaling.
RESULTS
Mutants Lacking RIG-3 Are Hypersensitive to Aldicarb
To identify new molecules involved in neuromuscular signaling,
we used RNAi to screen for cell adhesion molecules whose
absence alters the responsiveness of Caenorhabditis elegans
to the acetylcholinesterase inhibitor aldicarb. Aldicarb treatment
causes acute paralysis due to the accumulation of acetylcholine
(ACh) in the synaptic cleft at the neuromuscular junction (NMJ).
Gene inactivations that alter synaptic function can cause either
resistance or hypersensitivity to aldicarb (Miller et al., 1996;
Sieburth et al., 2005; Vashlishan et al., 2008). For this screen,Neuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc. 103
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Figure 1. Inactivation of rig-3 Causes Hypersensitivity to Aldicarb
(A) A schematic of the RIG-3 protein is shown, indicating the signal sequence
(ss), Ig, FNIII, and GPI- anchoring domains, and the site utilized for mCherry
tagging. The domains deleted in rig-3(ok2156) mutants are indicated by
the bar.
(B) Aldicarb-induced paralysis is compared after RNAi treatments with rig-3
and two negative controls, empty vector (vector) and eri-1. The number of
replicate experiments for each RNAi treatment (>20 animals/replicate) is
indicated.
(C) Aldicarb-induced paralysis is shown for the indicated genotypes. RIG-3
transgenes are as follows: ACh neurons (unc-17 promoter), gut (vha-6
promoter), GABA (unc-25 promoter), RIG-3 (mCherry-tagged rig-3 genomic
construct), TMD (membrane-anchored RIG-3 expressed in ACh neurons),
DGPI (constitutively secreted RIG-3 expressed in ACh neurons). The number
of trials (20 animals/trial) is indicated for each genotype. Values that
differ significantly from wild-type (***, p < 0.001) and from rig-3 mutants (###,
p < 0.001) are indicated. Error bars represent standard error of mean (SEM).
Neuron
RIG-3 Prevents Synaptic Potentiationwe selected a collection of 216 putative cell adhesionmolecules,
based on the presence of protein domains found in CAMs (data
not shown).
A gene identified in this screen was rig-3, which encodes
a GPI-anchored protein containing two Ig domains and a diver-
gent fibronectin type III (FNIII) domain (Figure 1A). RIG-3 has
a pattern of protein domains that is similar to the Drosophila
proteins Klingon and Wrapper, and to mammalian NCAMs
(Cox et al., 2004; Yamagata et al., 2003). RIG-3 was previously104 Neuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc.implicated in axon guidance in C. elegans; however rig-3 single
mutants do not show guidance defects (Schwarz et al., 2009).
Inactivation of rig-3 by RNAi caused significant hypersensi-
tivity to aldicarb (Figure 1B) and a similar defect was observed
in homozygous rig-3(ok2156) mutants (Figure 1C). The ok2156
mutation deletes 1.5 kb of the rig-3 gene, spanning exons 2–5
(including most of the Ig domains and part of the FNIII domain);
consequently, ok2156 is likely to cause a severe loss of gene
function (www.wormbase.org) (Figure 1A) (Schwarz et al., 2009).
The rig-3 aldicarb hypersensitivity defect was rescued by
transgenes driving RIG-3 expression in all neurons (utilizing the
snb-1 Synaptobrevin promoter, data not shown) and in cholin-
ergic neurons (utilizing the unc-17 VAChT promoter) (Figure 1C).
By contrast, rig-3 transgenes expressed in GABA neurons, or in
the intestine lacked rescuing activity (Figure 1C). None of these
transgenes altered aldicarb responsiveness of wild-type animals
(data not shown). These results suggest that RIG-3 functions in
cholinergic neurons to regulate some aspect of neuromuscular
function or development.
Prior work showed that rig-3 is expressed in neurons and in the
intestine (www.wormbase.org) (Schwarz et al., 2009). A
construct containing the full rig-3 genomic region, with mCherry
inserted just after the signal sequence (Figure 1A), was ex-
pressed in ventral cord motor neurons but not in body muscles
(Figure 2A and data not shown). To identify the rig-3 expressing
motor neurons, we performed several double labeling experi-
ments. The rig-3 construct was coexpressed with acr-2 (A, B,
and AS neurons), unc-4 (VA and DA neurons), unc-129 (DA
neurons), but not with ceh-12 (VB neurons) reporters, which
are expressed in the indicated motor neuron classes (Figure 2;
see Figure S2 available online; data not shown). These results
suggest that RIG-3 is expressed in the VA and DAmotor neurons
(and possibly the AS neurons).
To determine the subcellular localization of the RIG-3 protein,
we analyzed the expression of mCherry-tagged RIG-3. The
mCherry::RIG-3 genomic construct rescued the rig-3 aldicarb
defect (Figure 1C), demonstrating that this chimeric protein re-
tainedRIG-3 function.mCherry::RIG-3was distributed in a punc-
tate pattern in dorsal cord axons, and the RIG-3 puncta fluores-
cence was partially colocalized with the SV protein SNB-1,
consistent with RIG-3 enrichment at presynaptic elements (Fig-
ure 2B). RIG-3 fluorescence was also observed in coelomocytes
(Figure 2C), which are phagocytic cells that internalize proteins
secreted into the body cavity (Fares and Grant, 2002). The coe-
lomocyte fluorescence most likely corresponds to RIG-3 shed
from neuronal membranes (perhaps due to hydrolysis of the
GPI-anchor). Thus, RIG-3 may function as either a cell surface
or a secreted protein. A control construct expressing cyto-
plasmic mCherry in cholinergic motor neurons did not produce
coelomocyte fluorescence (Figure 2D).
We did several experiments to test the functional importance
of membrane-tethered and secreted RIG-3. A RIG-3 construct
lacking the C-terminal GPI-anchoring signal, RIG-3(DGPI),
exhibited decreased axonal and increased coelomocyte fluores-
cence (Figure S1), and failed to rescue the aldicarb hypersensi-
tivity defect of rig-3 mutants (Figure 1C). Furthermore, RIG-3
expressed in GABA neurons (with the unc-25 promoter) did not
rescue the aldicarb hypersensitivity seen in rig-3 mutants
10 m
RIG-3
SNB-1
Merge
10 m
RIG-3
A
B
C
ACR-2
RIG-3
Merge
mCherry
10 m
D
10 m
Figure 2. RIG-3 Is Expressed in ACh Neurons
(A) The mCherry-tagged rig-3 genomic construct is expressed in cholinergic
motor neurons, which are identified by expression of the acr-2::gfp reporter.
Arrows indicate the cholinergic neurons that express RIG-3.
(B) Distribution of mCherry::RIG-3 (expressed with the rig-3 promoter) and
GFP::SNB-1 (expressed in DA neurons with the unc-129 promoter) are
compared in dorsal cord axons.
(C) mCherry::RIG-3 fluorescence in coelomocytes is shown.
(D) Soluble mCherry (expressed in cholinergic neurons) did not label
coelomocytes.
Neuron
RIG-3 Prevents Synaptic Potentiation(Figure 1C), as would be predicted if secreted RIG-3 lacks
rescuing activity. By contrast, a transgene expressing a constitu-
tively membrane-anchored protein, RIG-3(TMD), in cholinergic
neurons produced axonal fluorescence, lacked coelomocyte
fluorescence, and partially rescued the aldicarb hypersensitivity
defect (Figure 1C; Figure S1). These results indicate that the
synaptic function of RIG-3 is primarily mediated by membrane-
associated RIG-3 at presynaptic elements and not by secreted
RIG-3.
Synapse Morphology Is Normal in rig-3 Mutants
The rig-3 aldicarb defect could arise from altered development
of neurons or synapses. We did several experiments to address
this possibility. The number of ventral cord neurons and their
axon morphologies were unaltered in rig-3 mutants (data not
shown), consistent with prior studies (Schwarz et al., 2009).We also analyzed the morphology of neuromuscular junctions
with several synaptic markers. We found no significant differ-
ences in the morphology, fluorescence intensity, or density of
cholinergic and GABAergic NMJs in rig-3 mutants using
GFP-tagged SNB-1 Synaptobrevin and SYD-2 a-liprin (an
active zone protein) as markers (Figures S2C and S2D;
data not shown). Adhesion molecules often anchor the cortical
actin cytoskeleton to the plasma membrane (Leshchyns’ka
et al., 2003). To analyze the actin cytoskeleton at synapses,
we expressed two GFP-tagged actin-binding proteins in
cholinergic neurons (GSNL-1 gelsolin and SNN-1 synapsin).
GSNL-1 and SNN-1 fluorescence were unaltered in rig-3
mutants, indicating a relatively normal actin cytoskeleton (Fig-
ure S2E; data not shown). These results indicate that rig-3
mutants do not have significant defects in synapse formation
or maintenance.
Baseline Synaptic Transmission Is Normal
in rig-3 Mutants
We did several experiments to determine if the rig-3 aldicarb
defect is caused by changes in baseline synaptic transmission.
To assay synaptic transmission, we recorded excitatory and
inhibitory postsynaptic currents (EPSC and IPSC) from body
muscles. The amplitude and rate of endogenous EPSCs and
IPSCs were not altered in rig-3mutants, indicating that baseline
cholinergic and GABAergic transmission were both normal (Fig-
ure 3A; Figure S3). The amplitude and total synaptic charge of
EPSCs evoked by a depolarizing stimulus were also unaltered
(Figure 3B). To assess changes in postsynaptic AChRs, we
analyzed expression of ACR-16 receptors. ACR-16::GFP puncta
fluorescence was slightly increased in rig-3 mutants compared
to wild-type controls (15%, p < 0.01) (Figure 4A); however, the
amplitude of currents evoked by bath applied ACh were not
altered in rig-3 mutants, suggesting that muscle sensitivity to
ACh was normal (Figure 3C). Taken together, these results
indicate that inactivation of RIG-3 does not significantly alter
baseline synaptic transmission.
Aldicarb Induces Increased Muscle Sensitivity
to ACh in rig-3 Mutants
We recently showed that ACh release at NMJs is enhanced after
brief treatments with aldicarb (Hu et al., 2011). Thus, the rig-3
aldicarb defect could result from an exaggeration of this aldicarb
mediated presynaptic potentiation. To test this idea, we
measured the effect of aldicarb treatment on EPSC rates. A
60 min aldicarb treatment caused identical increases in the
EPSC rate of both wild-type and rig-3mutants (Figure 3A). These
results suggest that the rig-3 aldicarb hypersensitivity defect
was not caused by increased ACh release.
Several results suggest that rig-3 mutant muscles have
increased responsiveness to ACh after aldicarb treatment. We
used three assays to measure muscle ACh responses: the
amplitudes of endogenous EPSCs, of stimulus evoked EPSCs,
and of currents activated by exogenously applied ACh. Aldi-
carb treatment increased the amplitude of endogenous EPSCs
recorded from rig-3 mutant muscles whereas those recorded
from wild-type animals were unaltered (Figure 3A; Figures
S3B and S3C). Aldicarb had no effect on the decay kineticsNeuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc. 105
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Figure 3. Aldicarb Treated rig-3 Mutants
Show an Increased Postsynaptic
Responses
Endogenous EPSCs (A), stimulus-evoked EPSCs
(B), and ACh-evoked currents (C) were recorded
from body wall muscle of adult worms of the
indicated genotypes, with (black) and without
(gray) a 60 min aldicarb treatment. Representative
traces of endogenous EPSCs, averaged traces
of stimulus-evoked responses and ACh-evoked
responses, and summary data for all three are
shown. Rescue (resc) refers to rig-3 mutants
containing a transgene expressing RIG-3 in
cholinergic neurons (with the unc-17 promoter).
The number of animals analyzed is indicated for
each genotype. Values that differ significantly
from untreated wild-type (***, p < 0.001) and from
untreated rig-3 mutants (###, p < 0.001) are indi-
cated. Error bars represent SEM.
Neuron
RIG-3 Prevents Synaptic Potentiationof endogenous EPSCs in rig-3 or in wild-type controls (Fig-
ure S3B). The amplitude and total synaptic charge of evoked
responses in aldicarb treated rig-3 mutants were both signifi-
cantly greater than that observed in aldicarb treated wild-type
controls (Figure 3B). Aldicarb treatment also significantly
increased the amplitude of ACh-activated currents in rig-3
mutants whereas those recorded from wild-type animals were
significantly reduced (Figure 3C). The rig-3 defects in endoge-
nous EPSC, evoked EPSC, and ACh-activated currents were
all rescued by a rig-3 transgene expressed in cholinergic
neurons (Figure 3; Figure S3C). By contrast, aldicarb pretreat-
ment had no effect on the amplitude of endogenous IPSCs
recorded from either wild-type or rig-3 mutant muscles, sug-
gesting that body muscle responses to GABA were unaltered
(Figure S3A). Taken together, these results suggest that aldi-
carb enhances body muscle ACh responses in rig-3 mutants
(but not in wild-type controls) and that this effect is specific
for ACh responses.106 Neuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc.Aldicarb Increases the Synaptic
Abundance of ACR-16 Receptors
in rig-3 Mutants
Increased ACh responses could be
caused by altered expression or activity
of nicotinic AChRs. C. elegans body
muscles express two classes of nicotinic
AChRs, homomeric ACR-16 receptors
and heteropentameric ab-type receptors
that are sensitive to a synthetic agonist
levamisole. Levamisole (Lev) receptors
account for only 20% of the synaptic
and ACh-activated currents in body
muscles (Francis et al., 2005; Touroutine
et al., 2005). After aldicarb treatment,
ACR-16::GFP puncta fluorescence was
significantly increased in rig-3 mutants
(35%, p < 0.001), while levels in wild-
type animals were unaltered (Figure 4A).
By contrast, aldicarb treatment had noeffect on UNC-29::GFP Lev receptor fluorescence nor on
UNC-49::GFP GABAA receptor fluorescence (consistent with
the unaltered IPSC amplitudes) in both wild-type and rig-3
mutants (Figure S4), indicating that this effect was specific for
ACR-16 receptors. This increase in ACR-16 fluorescence was
fully rescued by a transgene expressing RIG-3 in cholinergic
neurons (Figure 4A). Collectively, these results demonstrate
that inactivation of rig-3 reveals an aldicarb-induced potentiation
of synaptic transmission, which may result from increased
synaptic abundance of ACR-16 receptors.
The Effect of RIG-3 on ACR-16 Is Restricted to Adjacent
Postsynaptic Targets
Presynaptic RIG-3 could regulate postsynaptic receptors by
either of two general mechanisms. RIG-3 could act in a spatially
restricted manner, regulating ACR-16 levels in adjacent post-
synaptic membranes. Alternatively, RIG-3 expressed in one
neuron could regulate ACR-16 abundance at NMJs formed by
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Figure 4. Aldicarb Increases ACR-16 Synaptic
Abundance in rig-3 Mutants
(A) Representative images of dorsal cord ACR-16::GFP
fluorescence in aldicarb treated animals is shown for the
indicated genotypes. Summary data (right) for dorsal
ACR-16 puncta fluorescence is shown for control and
aldicarb treated animals of the indicated genotypes. ACh
rescue refers to rig-3 mutants containing a transgene ex-
pressing RIG-3 in all cholinergic neurons (using the unc-17
promoter).
(B) A schematic illustrating the morphology of a cholin-
ergic DA motor neuron (right) and representative images
of RIG-3 fluorescence in the dorsal and ventral cord
processes of DA neurons are shown (left). mCherry-tag-
ged RIG-3 was expressed in DA neurons (using the unc-
129 promoter).
(C and D) Representative images and summary data are
shown for dorsal (C) and ventral (D) ACR-16 puncta fluo-
rescence in the indicated genotypes. DA rescue refers to
rig-3 mutants containing a transgene expressing RIG-3
in DA neurons (using the unc-129 promoter). The number
of animals analyzed is indicated for each genotype. A
GFP-tagged ACR-16 construct was expressed in body
muscles (with themyo-3 promoter). ACR-16 puncta in the
dorsal and ventral cords correspond to postsynaptic
receptors at dorsal and ventral NMJs, respectively. Values
that differ significantly from aldicarb treated wild-type
controls are indicated (**, p < 0.01; ***, p < 0.001). Error
bars represent SEM.
Neuron
RIG-3 Prevents Synaptic Potentiationneighboring neurons. To distinguish between these possibilities,
we examined the effect of RIG-3 expression in the DA motor
neurons. DA neurons have cell bodies in the ventral midline,
they extendadendritic process in theventral cord (which receives
synaptic input from interneurons), and an axonal process in the
dorsal cord (which forms NMJs with dorsal body muscles) (Fig-
ure 4B). mCherry-tagged RIG-3 expressed in DA neurons was
targeted to puncta in dorsal cord axons whereas little RIG-3
fluorescence was observed in the DA ventral cord processes
(Figure 4B), consistent with presynaptic targeting of RIG-3 (Fig-
ure 2B). Transgenes expressing RIG-3 in DA neurons rescued
the rig-3 ACR-16 fluorescence defect in the dorsal cord, but did
not rescue the ACR-16 defect in the ventral cord (Figures 4C
and4D) nor the rig-3 aldicarb paralysis defect (FigureS4C). These
results suggest that the active formof RIG-3 is restricted to axons
and that RIG-3 functions in a spatially restricted manner, regu-
lating ACR-16 levels in adjacent postsynaptic membranes.Neuron 71ACR-16 Receptors Are Required
for Aldicarb-Induced Potentiation
of rig-3 Mutant Synapses
Increased ACR-16 targeting to synapses could
provide a mechanism to explain the aldicarb-
induced enhancement of synaptic transmission
in rig-3 mutants. Consistent with this idea, the
aldicarb hypersensitivity, the increased EPSC
amplitudes, and the increased ACh-activated
current after aldicarb treatment were all elimi-
nated in acr-16; rig-3 double mutants (Figure 5).
The residual ACh-activated current in acr-16
mutants are a direct measure of Lev receptorfunction; consequently, this double mutant analysis demon-
strates that ACR-16 receptors are absolutely required for the
synaptic effects of RIG-3, and changes in Lev receptor mediated
currents are not observed in rig-3 mutants. Overexpression of
ACR-16 in wild-type body muscles also produced hypersensi-
tivity to aldicarb (Figure 5A), suggesting that increased ACR-16
levels are sufficient to cause this defect. However, increased
expression of the acr-16 gene is unlikely to explain the rig-3
mutant phenotype because quantitative PCR did not detect
significant changes in acr-16 mRNA levels after aldicarb treat-
ment: acr-16 mRNA levels after aldicarb treatment (normalized
to untreated controls) rig-3 = 0.80 ± 0.09, wild-type = 0.77 ±
0.13. These results suggest that aldicarb regulates ACR-16
in a posttranscriptional manner in rig-3 mutants, thereby
enhancing synaptic transmission. These results also indicate
that changes in ACR-16 can account for all of the rig-3 synaptic
defects., 103–116, July 14, 2011 ª2011 Elsevier Inc. 107
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Figure 5. ACR-16 Is Required for Aldicarb-Induced Potentiation of Postsynaptic Responses in rig-3 Mutants
(A) Summary data is shown for aldicarb-induced paralysis in the indicated genotypes. Transgenic animals overexpressing ACR-16 (ACR-16 OE) are indicated.
The number of trials (20 animals/trial) is indicated for each genotype.
(B–D) Traces and summary data for endogenous EPSCs (B), evoked EPSCs (C), and ACh-activated currents (D) are shown for control and aldicarb treated
animals of the indicated genotypes. For endogenous EPSCs, representative traces are shown. For evoked EPSCs and ACh-activated EPSCs, averaged traces
are shown. The number of animals analyzed is indicated for each genotype. Values that differ significantly from wild-type controls are indicated (***, p < 0.001;
*, p < 0.05). Error bars represent SEM.
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RIG-3 Prevents Synaptic PotentiationACR-16 Mobility in the Nerve Cord Is Increased
in rig-3 Mutants
The receptors present at a synapse are provided by the dynamic
exchange between a mobile pool of receptors, and receptors
bound at postsynaptic elements (Opazo and Choquet, 2011).
To determine how RIG-3 alters this equilibrium, we analyzed108 Neuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc.fluorescence recovery after photobleaching (FRAP) of
ACR-16::GFP puncta in the dorsal nerve cord (Figure 6). The
ACR-16 FRAP observed in untreated wild-type controls and
rig-3 mutants were not significantly different. After aldicarb
treatment, FRAP was significantly increased in rig-3 mutants,
but was unaltered in wild-type controls. By contrast FRAP of
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Figure 6. RIG-3 Regulates ACR-16 Delivery to
Postsynaptic Elements
Representative images (A) and summary data (B) are
shown for FRAP of ACR-16::GFP at dorsal cord NMJs of
control and aldicarb treated animals. At time 0, ACR-16
fluorescence in a 2 mm box encompassing a single punc-
tum was photo bleached. ACR-16 fluorescence was
subsequently measured at the photo bleached and
a neighboring control punctum. The fractional recovery of
fluorescence 45 min after photobleaching is shown (B).
The fluorescence of control unbleached puncta did not
change significantly after 45 min of imaging (data not
shown). The number of animals analyzed is indicated for
each genotype. Values that differ significantly from wild-
type controls are indicated (**, p < 0.01). Error bars
represent SEM.
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RIG-3 Prevents Synaptic PotentiationUNC-49::GFP (GABAA receptor) was unaltered by aldicarb
treatment in both wild-type and rig-3mutants (Figure S5). These
experiments indicate that aldicarb treatment significantly
increased the population of mobile ACR-16 receptors in rig-3
mutants, but not in wild-type controls. These results support
the idea that RIG-3 restricts the exchange between synaptic
and mobile ACR-16 receptors, and that it does so by control-
ling the number of mobile receptors available for synaptic
recruitment.
CAM-1 Is Required for RIG-3 Regulation of ACR-16
A prior study showed that CAM-1, a Ror-type receptor tyrosine
kinase (RTK), promotes ACR-16 delivery to NMJs, but does
not regulate Lev receptor levels (Francis et al., 2005). Consistent
with this study, we observed modestly reduced synapticNeuron 71ACR-16::GFP fluorescence (78% wild-type,
p < 0.01) and endogenous EPSC amplitudes
(80% wild-type, p < 0.001) in cam-1 mutants
(Figures 7A and 7B). The cam-1 null mutation
did not eliminate synaptic ACR-16 receptors,
as indicated by the residual ACR-16 synaptic
fluorescence (Figure 7B), and by the fact that
the endogenous EPSC amplitude observed in
acr-16 mutants (48% wild-type, p < 0.001; Fig-
ure 7A) were significantly smaller than those
observed in cam-1 null mutants. Thus, synaptic
ACR-16 levels are reduced but not eliminated in
cam-1 mutants.
CAM-1 and RIG-3 have opposite effects on
synaptic ACR-16 levels and both selectively
regulate ACR-16, having little effect on Lev
receptors (Francis et al., 2005). Prompted by
these results, we tested the idea that the effects
of RIG-3 on ACR-16 are mediated by changes
in CAM-1 activity. Consistent with this idea,
the aldicarb hypersensitivity, the increased
endogenous EPSC amplitudes, and the in-
creased ACR-16::GFP levels after aldicarb
treatment were all eliminated in cam-1; rig-3
double mutants (Figures 7A–7C). To determine
if RIG-3 regulates CAM-1 levels, we analyzedGFP-tagged CAM-1 fluorescence in body muscles. Aldicarb
treatment significantly increased CAM-1 puncta fluorescence
in the nerve cord of rig-3 mutants, but had no effect on CAM-1
levels in wild-type controls (Figure 7D). Taken together, these
results suggest that RIG-3 negatively regulates CAM-1 levels
at NMJs, and that increased CAM-1 activity is required for the
effects of RIG-3 on ACR-16.
Several prior studies showed that CAM-1 binds secreted Wnt
ligands and functions as a Wnt receptor or as an antagonist
inhibiting signaling by other Wnt receptors (Green et al., 2008).
Prompted by these results, we wondered if the effects of
RIG-3 on synaptic transmission could result from changes in
Wnt signaling at the NMJ. Consistent with this idea, we found
that a mig-14 Wntless mutation, which reduces Wnt secretion
(Myers and Greenwald, 2007; Pan et al., 2008; Yang et al.,, 103–116, July 14, 2011 ª2011 Elsevier Inc. 109
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Figure 7. CAM-1 Wnt Receptors Are Required for the Effects of RIG-3 on ACR-16
(A) Averaged traces and summary data are shown for endogenous EPSCs of control and aldicarb treated animals. The number of animals analyzed is indicated for
each genotype.
(B and C) Representative images and summary data are shown for dorsal cord ACR-16::GFP (B) and ventral cord CAM-1::GFP fluorescence (C) in control and
aldicarb treated animals. The number of animals analyzed is indicated for each genotype. GFP-tagged ACR-16 and CAM-1 were expressed in body muscles
(using the myo-3 promoter).
(D and E) Summary data is shown for aldicarb-induced paralysis in the indicated genotypes. The number of trials (20 animals/trial) is indicated for each
genotype. In panel E, all strains (including the wild-type control) contain the zdIs5 transgene, which expresses GFP in the touch neurons. Values that differ
significantly from wild-type controls are indicated (***, p < 0.001; *, p < 0.05). Error bars represent SEM.
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RIG-3 Prevents Synaptic Potentiation2008), confers resistance to aldicarb-induced paralysis and elim-
inates the rig-3 aldicarb hypersensitivity defect in mig-14; rig-3
double mutants (Figure 7E), implying that Wnt secretion is110 Neuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc.required for RIG-3’s effects on aldicarb responsiveness.
MIG-14 and CAM-1 regulate Wnt signaling in several develop-
mental pathways, and have not been implicated in any other
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Figure 8. RIG-3 Antagonizes the Effects of Wnt on ALM Polarity
(A) Expression of the mCherry-tagged rig-3 genomic construct is shown in ALM neurons. The ALM neurons were visualized with the zdIs5 transgene, which
expresses GFP in the touch neurons (with the mec-4 promoter).
(B) Representative images and schematic drawings are shown illustrating wild-type, bipolar (less severe), and reversed (more severe) ALM defects.
(C) Summary data for ALM polarity defects are shown for the indicated genotypes. The number of animals analyzed is indicated for each genotype. All strains
contain the zdIs5 transgene, to allow visualization of ALM neurons. Values that differ significantly fromwild-type controls are indicated (***, p < 0.001; **, p < 0.01).
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RIG-3 Prevents Synaptic Potentiation(i.e., non-Wnt) signaling pathways; consequently, these results
strongly support the idea the effects of RIG-3 on the NMJ are
mediated by changes in Wnt signaling.
RIG-3 Alters Wnt Regulation of ALM Polarity
The effects of RIG-3 on CAM-1 at NMJs suggest that RIG-3
might also regulate Wnt signaling in other tissues. To test this
idea, we analyzed the anteroposterior polarity of the ALM me-
chanosensory neurons. Several prior studies showed that ALM
polarity is regulated by Wnt signaling (Hilliard and Bargmann,
2006; Prasad and Clark, 2006). The mCherry-tagged rig-3
genomic construct was expressed in ALM neurons (Figure 8A),suggesting that RIG-3 could play a role in Wnt mediated control
of ALM polarity. In wild-type animals, ALM neurons have a single
anteriorly directed process (Figures 8B and 8C). In mutants with
decreased Wnt signaling, ALM neurons exhibit either of two
defects, with some neurons having both an anterior and a poste-
rior process (bipolar ALMs) while others have a single posteriorly
directed process (reversed ALMs) (Figures 8B and 8C) (Fleming
et al., 2010; Prasad and Clark, 2006). The prevalence of bipolar
and reversed ALM neurons differs among Wnt mutants. These
differences in ALM defects likely result from the fact that
C. elegans has five Wnt ligands, which have distinct effects on
ALM polarity. For example, two prior studies showed that theNeuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc. 111
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RIG-3 Prevents Synaptic Potentiationeffects of two Wnts (CWN-1 and EGL-20) on ALM polarity are
antagonized by a third Wnt (LIN-44) (Fleming et al., 2010; Prasad
and Clark, 2006). Thus, the precise ALM phenotype observed
is determined by how each mutation alters signaling by the
different Wnt ligands.
To further investigate if RIG-3 plays a role in Wnt signaling, we
analyzed the effect RIG-3 inactivation on ALM polarity in several
genetic backgrounds. Although ALM polarity was unaltered in
rig-3 single mutants, the rig-3 mutation significantly altered
ALM polarity defects caused by other Wnt pathway mutations
in double and triple mutants. Inactivating RIG-3 in cwn-1;
egl-20 double mutants decreased the severity of ALM polarity
defects: ALM reversals were significantly reduced in cwn-1;
egl-20; rig-3 triple mutants (p < 0.01, Fishers exact test), while
the number of bipolar ALMs was unaffected (p = 0.21, Fishers
exact test). Inactivating RIG-3 in mig-14 Wntless mutants
decreased ALM reversals and increased bipolar ALMs (Figures
8B and 8C). The different outcome in mig-14 mutants likely
results from the fact that MIG-14 is required for secretion of all
Wnt ligands. By contrast, the rig-3 mutation had no effect on
ALM polarity in two strains lacking CAM-1, i.e., cam-1; rig-3
double mutants and cam-1 mig-14; rig-3 triple mutants (Fig-
ure 8C). These results lead to three conclusions. First, RIG-3
plays an important role in Wnt regulation of ALM polarity.
Second, CAM-1 is absolutely required for the effects of RIG-3
on ALM polarity. Third, the effects of RIG-3 on ALM polarity
and on ACR-16 levels at the NMJ can both be explained by
changes in Wnt signaling.
DISCUSSION
Our results lead to six primary conclusions. First, RIG-3 acts in
motor neurons to prevent a form of postsynaptic plasticity that
is induced by aldicarb treatment. Second, inactivating RIG-3
has no effect on baseline synaptic transmission, suggesting
that the function of RIG-3 is required only during aldicarb-
induced plasticity. Third, the synaptic potentiation observed
in rig-3 mutants is mediated by aldicarb-induced accumulation
of postsynaptic ACR-16 nAChR receptors. Fourth, RIG-3
decreases the number of mobile ACR-16 receptors available
for recruitment into postsynaptic receptor fields. Fifth, inactivat-
ing RIG-3 also alters the polarity of ALM neurons. And sixth, the
effects of RIG-3 on cholinergic transmission and on ALM polarity
are both mediated by changes in Wnt signaling, and in particular
by inhibiting the activity of a Wnt-binding protein (CAM-1).
Below, we discuss the significance of these findings.
RIG-3 Regulates Wnt Signaling
Several results suggest that RIG-3 inhibits the function of
CAM-1. First, aldicarb treatment increased CAM-1 levels at
NMJs in rig-3 mutants, but not in wild-type controls. Second,
a cam-1 null mutation eliminated the effects of RIG-3 on aldicarb
responses, EPSCs, ACR-16 levels, and ALM polarity. This
double mutant analysis is particularly informative. The cam-1
mutation completely occludes the effects of RIG-3 on ACR-16
trafficking, despite the fact that ACR-16 levels are only modestly
reduced in cam-1 mutants (80% wild-type levels). These
results provide strong genetic evidence that CAM-1 acts down-112 Neuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc.stream of RIG-3. Thus, both double mutant analysis and imaging
data support the idea that RIG-3 regulates ACR-16 and ALM
polarity through changes in CAM-1 activity. The effects of
RIG-3 on CAM-1 levels could occur through a variety of mecha-
nisms. RIG-3 and CAM-1 both contain Ig domains, which could
mediate direct binding interactions between these proteins.
Alternatively, RIG-3 could inhibit Wnt secretion or Wnt binding
to CAM-1 or other Wnt receptors.
CAM-1 can function as a receptor mediating the effects of
Wnt ligands or as an antagonist inhibiting Wnt binding to other
Wnt receptors (Green et al., 2008). Despite this ambiguity, all
of the known effects of CAM-1 on development are mediated
by changes in Wnt signaling (Green et al., 2008). Thus, absolute
requirement of RIG-3 for CAM-1 suggests that the effects of
RIG-3 on synaptic transmission and on ALM polarity are both
mediated by changes in Wnt signaling.
RIG-3 inhibition of CAM-1 could potentially promote or inhibit
Wnt signaling, depending on whether CAM-1 functions as a
receptor or an antagonist. Consequently, to assess how RIG-3
alters Wnt signaling, we compared the effect of rig-3 mutations
to those caused by mutations inactivating Wnt ligands or
decreasing Wnt secretion. At the NMJ, a mig-14 Wntless muta-
tion and a rig-3 mutation had opposite effects on aldicarb-
inducedparalysis and theeffect ofRIG-3onaldicarb-responsive-
ness was eliminated in mig-14; rig-3 double mutants. These
results suggest that RIG-3 regulates aldicarb responses by inhib-
iting Wnt signaling at the NMJ.
For ALM polarity, the results are more complicated. Prior
studies showed that four Wnt ligands play a role in dictating
ALM polarity but that distinct ALM defects (i.e., bipolar versus
reversed ALM neurons) are observed when different combina-
tions of Wnts are inactivated (Fleming et al., 2010; Prasad and
Clark, 2006). Two results suggest that a global reduction in Wnt
signaling primarily leads to reversed ALM neurons: quintuple
mutants containing mutations in all five Wnt ligands (55%
reversed, 5% bipolar) (Fleming et al., 2010) andmig-14 mutants
(which reduce secretion of all Wnt ligands) (69% reversed, 12%
bipolar) (Figure 8). These data indicate that the different ALM
phenotypes observed in Wnt mutants are analogous to an allelic
series whereby more extreme Wnt defects cause primarily ALM
reversals while less severe defects cause fewer reversals and
increased bipolar ALMs. Inactivating RIG-3 in cwn-1; egl-20
double mutants significantly decreased reversed ALMs and
had no effect on bipolar ALMs, indicating that RIG-3 and these
twoWnt ligands have opposite effects onALMpolarity. Inactivat-
ing RIG-3 inmig-14mutants also resulted in a less severe pheno-
type (with decreased ALM reversals and increased bipolar
ALMs). In both experiments, rig-3 mutations and mutations
inactivating Wnt signaling had opposite effects on ALM polarity.
Thus, analysis of the effects of RIG-3 on the NMJ and on ALM
polarity both support the idea that RIG-3 normally inhibits Wnt
signaling. These results do not exclude the possibility that
RIG-3 promotes Wnt signaling in other contexts. In particular,
in cases where CAM-1 functions as a Wnt antagonist, RIG-3
inhibition of CAM-1 could enhance Wnt signaling.
Wnts have been implicated inmany aspects of neuronal devel-
opment, including axon guidance, cell migrations, and synapse
formation (Budnik and Salinas, 2011). Although Wnts are often
Neuron
RIG-3 Prevents Synaptic Potentiationinvolved in regulating development, several results suggest that
RIG-3’s and CAM-1’s effects on ACR-16 trafficking are not
mediated by changes in synapse development. Inactivation of
RIG-3 had no effect on synapse morphology nor on baseline
synaptic transmission at adult cholinergic and GABAergic
NMJs, suggesting that development of these synapses had
not been altered. Instead, a rig-3 synaptic defect was apparent
only after treating adult animals with aldicarb, implying the
RIG-3 is required for aldicarb-induced plasticity. Postsynaptic
responses at these cholinergic NMJs are mediated two classes
of nicotinic receptors (i.e., ACR-16 and Lev receptors). In rig-3
mutants, aldicarb treatment increased ACR-16 levels and
ACR-16-mediated currents, but had no effect on UNC-29 Lev
receptor levels nor on Lev receptor-mediated currents. These
results argue strongly against a developmental basis for the
rig-3 synaptic defect because disruptions of synapse or muscle
development would alter both postsynaptic receptors equally,
and would not be contingent on aldicarb treatment. For these
reasons, we propose that RIG-3 regulates Wnt signals involved
in both neural development (ALM polarity) and synaptic plasticity
(ACR-16 trafficking).
Wnts are implicated in several other examples of synaptic
plasticity. For example, activity evokes Wnt secretion in both
Drosophila and in rodent hippocampal neurons, mediating
activity dependent plasticity in both cases (Ataman et al., 2008;
Chen et al., 2006).
Implications for Wnt Signaling
Several other Wnt antagonists have been described (Kawano
and Kypta, 2003). For example, secreted frizzled-related
proteins (SFRPs) bind Wnt ligands, inhibiting their signaling.
Secreted Dickkopf proteins bind to low density lipoprotein
receptor related proteins (LRPs), which are accessory subunits
for Frizzled receptors, thereby inhibiting Wnt signaling. We
show that RIG-3 inhibits CAM-1, a receptor mediating nonca-
nonical Wnt signaling. These results suggest that different
inhibitors are utilized to inhibit canonical and noncanonical Wnt
pathways. Prior studies focused primarily on the developmental
effects of Wnt antagonists. Our results suggest that RIG-3 (and
potentially other Wnt antagonists) could also regulate activity-
induced synaptic plasticity in mature animals. Like Wnts, several
other secreted morphogens have also been implicated in regu-
lating synaptic function, including IGFs, BMPs, and EGF related
ligands (Chiu and Cline, 2010; Keshishian and Kim, 2004; Mei
and Xiong, 2008). Antagonists have been identified for each of
these morphogens (Ferna´ndez-Gamba et al., 2009; Ghiglione
et al., 1999; Schweitzer et al., 1995; Smith, 1999). It will be inter-
esting to see if other morphogen antagonists also act as anti-
plasticity molecules.
RIG-3 Constrains Postsynaptic Plasticity
C. elegans has been extensively utilized as a model to study
synapse development and function. One limitation of this
model has been the absence of a paradigm for studying
synaptic plasticity. Our analysis of rig-3 mutants identified a
form of postsynaptic potentiation whereby a brief treatment
with aldicarb induces an increased abundance of postsyn-
aptic ACR-16 receptors and a corresponding increase in post-synaptic currents. By contrast, none of these effects were
observed after aldicarb treatment of wild-type controls. Collec-
tively, these results demonstrate that inactivation of RIG-3
reveals a form of plasticity whereby the activity-dependent
delivery of ACR-16 receptors to synapses is enhanced.
Analysis of vertebrate synapses has shown that receptors
mediating postsynaptic responses are supplied by a mobile
pool of receptors in the plasma membrane that are retained at
synapses by diffusional trapping (Opazo and Choquet, 2011).
We propose that RIG-3 regulates synaptic delivery of ACR-16
by an analogous mechanism. C. elegans NMJs are formed in
the dorsal and ventral nerve cords by en passant contacts
between motor neuron axons and processes extending from
body muscles (which are termed muscle arms). In rig-3mutants,
aldicarb treatment increases the mobile fraction of GFP-tagged
ACR-16 receptors in the nerve cord. These mobile ACR-16
receptors are likely in the plasma membrane of muscle arms,
as receptors residing in intracellular organelles are typically
immobile (Tardin et al., 2003). An increased number of mobile
ACR-16 receptors available for diffusional trapping would be ex-
pected to cause a corresponding increase in synaptic ACR-16
receptors (Opazo and Choquet, 2011).
Although RIG-3 regulates postsynaptic receptor trafficking,
RIG-3 functions in the presynaptic membrane. RIG-3 is
expressed in cholinergic motor neurons, is enriched near
presynaptic elements, and the active form of RIG-3 is tethered
to the presynaptic plasma membrane. Thus, the effects of
RIG-3 on ACR-16 levels are triggered from a presynaptic loca-
tion. Trans-synaptic regulation of ACR-16 levels by RIG-3 could
occur by a variety of mechanisms. Presynaptic RIG-3 could
antagonize signaling by secreted Wnt molecules. In this
scenario, one might expect that RIG-3 expressed in one motor
neuron would regulate ACR-16 levels at synapses formed by
neighboring neurons. Contrary to this idea, we found that the
effects of RIG-3 on ACR-16 are spatially restricted to nearby
postsynaptic elements, and possibly to direct postsynaptic
targets. Other potential mechanisms for trans-synaptic regula-
tion of ACR-16 levels include direct binding of RIG-3 to postsyn-
aptic CAM-1 receptors, or local regulation of Wnt binding to
CAM-1 expressed in postsynaptic partners. Further experiments
will be required to determine the precise mechanisms by which
RIG-3 and CAM-1 regulate ACR-16 trafficking.
RIG-3 regulated plasticity is similar in some respects to LTP at
hippocampal synapses in rodents. In both synapses, postsyn-
aptic currents are a composite of receptors with fast (ACR-16
and AMPA) and slow (Lev receptors and NMDA) kinetics, and
potentiation is mediated by increased delivery of fast receptors.
In this context, it is intriguing that some forms of LTP are disrup-
ted by interfering with Wnt signaling (Chen et al., 2006).
Aldicarb treatment also induces a form of presynaptic poten-
tiation (Hu et al., 2011). This presynaptic effect is mediated by
aldicarb-induced secretion of an endogenous neuropeptide
(NLP-12), which enhances ACh release at NMJs. Thus, the
C. elegans body wall cholinergic NMJ exhibits pre- and postsyn-
aptic forms of plasticity, both of which are induced by aldicarb
treatment, but which are mediated by distinct signaling path-
ways. It will be interesting to determine if these two forms of
aldicarb induced plasticity are coordinately regulated.Neuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc. 113
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Several adhesion molecules are known to promote recruitment
of postsynaptic receptors. In particular, Neuroligin-1 promotes
recruitment of glutamate receptors to synapses, whereas Neuro-
ligin-2 promotes recruitment of GABA receptors (Chih et al.,
2005; Graf et al., 2004). Several other families of cell surface
molecules also promote synaptic targeting of receptors,
including auxiliary subunits (e.g., TARPs) and CUB domain con-
taining proteins (e.g., SOL-1 and LEV-10) (Chen et al., 2000;
Gally et al., 2004; Zheng et al., 2004). Our results suggest that
cell surface IgSF proteins (like RIG-3) can also stabilize synaptic
signaling, by preventing plastic changes in postsynaptic
receptor fields. Thus, we propose that the dynamic behavior of
postsynaptic receptors is regulated by both positive and nega-
tive factors.
Antiplasticitymolecules likeRIG-3 couldplay important roles in
circuit development or function. In particular, we envisage two
potential functions for antiplasticity molecules. During develop-
ment, morphogens typically induce bistable signals, producing
switch-like changes in cellular fates. This property of morphogen
signaling could be particularly useful in the context of developing
circuits. During development, many circuits undergo activity-
dependent synaptic refinement, where plasticity in each circuit
is restricted to specific times during development, often referred
to as critical periods (Hensch, 2004). Thus, these forms of critical
period plasticity occur in a switch-like manner, opening and
closing during specific developmental time windows. We specu-
late that morphogens and their antagonists may provide
a biochemical mechanism for spatial and temporal patterning
of synaptic plasticity during development.
Antiplasticity molecules could also stabilize circuit function. It
has long been proposed that mechanisms must exist that
oppose correlation based rules for activity-dependent plasticity
(e.g., LTP and LTD) (Miller, 1996). These correlation based plas-
ticity rules are thought to confer instability on circuits because
repeated potentiation or depression would systematically shift
all synapses to higher or lower activities. Homeostatic plasticity
(or metaplasticity) has been proposed as a potential solution to
this problem (Pratt et al., 2003). We propose that antiplasticity
molecules may also perform this stabilizing function. Inappro-
priate changes in circuit activity could be prevented by expres-
sion of molecules such as RIG-3, whose function is to prevent
expression of plasticity. Conversely, mutations in antiplasticity
molecules would perturb circuit activity, and may contribute to
cognitive and behavioral disorders.EXPERIMENTAL PROCEDURES
Strains
Strains were maintained as described previously at 20C (Brenner, 1974).
OP50 Escherichia coli were used for feeding. The wild-type reference strain
was N2 Bristol. Descriptions of allele lesions can be found at www.
wormbase.org. The mutant strains used were: eri-1(mg366), lin-15B(n744),
rig-3(ok2156), acr-16(ok789), cam-1(ak37), mig-14(ga62), cwn-1(ok546), and
egl-20(n585).
RNAi Feeding Assay
RNAi assays were performed in the eri-1; lin-15b background (Wang et al.,
2005). RNAi clones utilized were previously described (Kamath and Ahringer,114 Neuron 71, 103–116, July 14, 2011 ª2011 Elsevier Inc.2003; Kamath et al., 2003). Acute aldicarb assays were performed in triplicate
on young adult worms by an experimenter unaware of the identity of the RNAi
clone utilized, all as described (Lackner et al., 1999). Aldicarb (Sigma and
Roche) concentration was 1 mM.
Fluorescence Microscopy and Quantitative Analysis
All quantitative imaging was done using a Olympus PlanAPO 1003 1.4 NA
objective and an ORCA100 CCD camera (Hamamatsu). Worms were immobi-
lized with 30 mg/ml BDM (Sigma). Imaging was done in either untreated
animals or after a 60 min exposure to 1 mM aldicarb. Line scans of dorsal
cord fluorescence were analyzed in Igor Pro (WaveMetrics) using custom-
written software (Burbea et al., 2002; Dittman and Kaplan, 2006). For coelomo-
cyte imaging, the posterior coelomocyte was imaged in larval stage 4 (L4) and
early adult worms (Sieburth et al., 2007). All p values indicated were based on
Student’s t tests.
ALM polarity was visualized with the integrated transgene zdIs5 [Pmec-
4::gfp], in animals immobilized with 1% sodium azide, using a Zeiss Axioskop2
microscope. The zdIs5 transgene is expressed in six mechanosensory
neurons, ALMs, PLMs, AVM, and PVM (Pan et al., 2008). For ALM, the bipolar
phenotype was defined as a normal anterior process and a posterior process
that is longer than five ALM cell diameters in length. p values were determined
by the Fisher exact test.
FRAP experiments were performed using the Olympus FV1000 confocal
microscope. Image stacks were captured, and maximum intensity projections
were obtained using Metamorph 7.1 software (Universal Imaging). For FRAP
experiments, the worms were immobilized in 10% agarose containing 0.5 ml
of 0.1 mm polystyrene microspheres (Polysciences). Animals were imaged at
5 and 10 min intervals until 55 or 65 min after photobleaching. To control for
motion artifacts, we measured fluorescence of neighboring unbleached
ACR-16 puncta. We excluded any experiments where the fluorescence of
neighboring puncta changed by >10% over the course of the experiment.
Electrophysiology
Electrophysiology was done on dissected adults as previously described
(Richmond and Jorgensen, 1999). All recording conditions were as described
previously (Sieburth et al., 2007). Aldicarb treatment refers to 60 min in 1 mM
aldicarb. For comparing average electrophysiological values, statistical
significance was determined using the Mann-Whitney test or Student’s
t test. For cumulative probability distributions, the Kolmogorov-Smirnov test
was used to determine statistical significance.
RIG-3 Constructs and Transgenes
Transgenic strains were generated by microinjection using several coinjection
markers: KP#1338 (pttx-3::GFP), KP#1480 (pmyo-2::NLS-mCherry), or
KP#1106 (pmyo-2::NLS-GFP) (Mello et al., 1991). Integrated transgenes con-
taining pmyo-3::ACR-16::GFP (nuIs299) and the pmyo-3::CAM-1::GFP
(nuIs465) were generated by UV mutagenesis. All of these constructs were
derivatives of pPD49.26 or pPD95.75 (Addgene).
Five RIG-3 constructs rescued rig-3(ok2156) mutants: KP#5918 (psnb-
1::RIG-3), KP#5914 (punc-17::RIG-3), KP#6005 (punc-17::mCherry::RIG-3),
KP#6292 (punc-17::mCherry::RIG-3TMD), and KP#6298 (prig-3::mCherry::
RIG-3). Three RIG-3 constructs did not rescue rig-3(ok2156) mutants:
KP #5915 (punc-25::RIG-3), KP#6012 (pvha-6::RIG-3), and KP#6305 (punc-
17::mCherry::RIG-3DGPI). The punc-129::mCherry::RIG-3 expresses RIG-3
in DA neurons, and was used to assess rescue of ACR-16 defects in the
dorsal versus ventral cords (KP#6008). All rescue constructs contained the
RIG-3 cDNA, with mCherry inserted between the amino acids 42 and 43.
The genomic mCherry::RIG-3 line was made using a 11kb RIG-3 genomic
fragment with mCherry inserted between amino acids 42 and 43. RIG-
3(DGPI) contains a deletion of the carboxy-terminal 23 amino acids. In
RIG-3(TMD), the carboxy-terminal 23 residues or RIG-3 were replaced by
transmembrane and cytoplasmic domains derived from NLG-1. Several
transgenes containing GFP-tagged synaptic proteins were previously
described: nuIs321 (punc-17::mCherry), nuEx379 (pacr-2::GFP), nuIs152
(punc-129::GFP::SNB-1), nuIs159 (punc-129::SYD-2::YFP), nuIs169 (punc-
129::GSNL-1::YFP) (Sieburth et al., 2005, 2007), zdIs5 (pmec-4::GFP)
Neuron
RIG-3 Prevents Synaptic Potentiation(Pan et al., 2008), akIs38 (UNC-29::GFP), (Francis et al., 2005) and nuIs283
(pmyo-3::UNC-49::GFP) (J. Bai and J.M.K., unpublished data).
Quantitative PCR Experiments
For real-time PCR experiments, late L4 and early adult wormswere transferred
to mock treatment plates or plates containing 1 mM aldicarb for 1 hr after
which the RNA from these animals was harvested and quantitative PCR
performed as detailed in Simon et al. (2008).
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